New research suggests that common cholesterol-lowering drugs like statins and ezetimibe may slow Alzheimer's progression. While promising, more studies are needed to confirm these findings. This could be a significant step toward repurposing existing medications to combat Alzheimer's disease.
Recent studies suggest that statins, commonly prescribed to lower cholesterol, may also slow cognitive decline in Alzheimer's patients. Research from Karolinska Institutet indicates that Alzheimer's patients on statin therapy experience slower cognitive decline compared to those not on statins. While these findings are promising, further clinical trials are necessary to confirm the benefits of statins in Alzheimer's treatment.
Similarly, researchers at the University of Arkansas for Medical Sciences have discovered that ezetimibe, another cholesterol-lowering drug, may disrupt the progression of Alzheimer's and other dementias. Their study found that patients taking ezetimibe had a significantly lower incidence of Alzheimer's compared to those not on the medication. However, additional studies are needed to confirm its effectiveness and safety for at-risk groups.
These developments offer hope for repurposing existing cholesterol medications to combat Alzheimer's disease.
